Literature DB >> 10429676

Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.

C Chiodoni1, P Paglia, A Stoppacciaro, M Rodolfo, M Parenza, M P Colombo.   

Abstract

We transduced BALB/c-derived C-26 colon carcinoma cells with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand (CD40L) genes to favor interaction of these cells with host dendritic cells (DCs) and, therefore, cross-priming. Cotransduced cells showed reduced tumorigenicity, and tumor take was followed by regression in some mice. In vivo tumors were heavily infiltrated with DCs that were isolated, phenotyped, and tested in vitro for stimulation of tumor-specific cytotoxic T lymphocytes (CTLs). BALB/c C-26 carcinoma cells express the endogenous murine leukemia virus (MuLV) env gene as a tumor-associated antigen. This antigen is shared among solid tumors of BALB/c and C57BL/6 mice and contains two epitopes, AH-1 and KSP, recognized in the context of major histocompatibility complex class I molecules H-2Ld and H-2K(b), respectively. DCs isolated from C-26/GM/CD40L tumors grown in (BALB/c x C57BL/6)F1 mice (H-2d x b) stimulated interferon gamma production by both anti-AH-1 and KSP CTLs, whereas tumor-infiltrating DCs (TIDCs) of BALB/c mice stimulated only anti-AH-1 CTLs. Furthermore, TIDCs primed naive mice for CTL activity as early as 2 d after injection into the footpad, whereas double-transduced tumor cells required at least 5 d for priming; this difference may reflect direct DC priming versus indirect tumor cell priming. Immunohistochemical staining indicated colocalization of DCs and apoptotic bodies in the tumors. These data indicate that DCs infiltrating tumors that produce GM-CSF and CD40L can capture cellular antigens, likely through uptake of apoptotic bodies, and mature in situ to a stage suitable for antigen presentation. Thus, tumor cell-based vaccines engineered to favor the interaction with host DCs can be considered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10429676      PMCID: PMC2195555          DOI: 10.1084/jem.190.1.125

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  43 in total

Review 1.  Functions of CD40 on B cells, dendritic cells and other cells.

Authors:  C van Kooten; J Banchereau
Journal:  Curr Opin Immunol       Date:  1997-06       Impact factor: 7.486

2.  Constitutive class I-restricted exogenous presentation of self antigens in vivo.

Authors:  C Kurts; W R Heath; F R Carbone; J Allison; J F Miller; H Kosaka
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

3.  The best cytokine for the job.

Authors:  H I Levitsky
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

4.  Human renal-cell carcinoma tissue contains dendritic cells.

Authors:  M Thurnher; C Radmayr; R Ramoner; S Ebner; G Böck; H Klocker; N Romani; G Bartsch
Journal:  Int J Cancer       Date:  1996-09-27       Impact factor: 7.396

5.  Combined chemokine and cytokine gene transfer enhances antitumor immunity.

Authors:  D Dilloo; K Bacon; W Holden; W Zhong; S Burdach; A Zlotnik; M Brenner
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

6.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.

Authors:  A Y Huang; P H Gulden; A S Woods; M C Thomas; C D Tong; W Wang; V H Engelhard; G Pasternack; R Cotter; D Hunt; D M Pardoll; E M Jaffee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

7.  Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.

Authors:  C A Armstrong; R Botella; T H Galloway; N Murray; J M Kramp; I S Song; J C Ansel
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

8.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.

Authors:  M Cella; D Scheidegger; K Palmer-Lehmann; P Lane; A Lanzavecchia; G Alber
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

9.  Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help.

Authors:  S R Bennett; F R Carbone; F Karamalis; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

Review 10.  Mobilizing dendritic cells for tolerance, priming, and chronic inflammation.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

View more
  22 in total

Review 1.  Chemokines and dendritic cell traffic.

Authors:  S Sozzani; P Allavena; A Vecchi; A Mantovani
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

2.  Influence of granulocyte macrophage colony stimulating factor and tumor necrosis factor on anti-hepatoma activities of human dendritic cells.

Authors:  Jin-Kun Zhang; Jin-Lun Sun; Hai-Bin Chen; Yang Zeng; Yao-Jun Qu
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

3.  Antitumor activities of human dendritic cells derived from peripheral and cord blood.

Authors:  Jin-Kun Zhang; Jun Li; Hai-Bin Chen; Jin-Lun Sun; Yao-Juan Qu; Juan-Juan Lu
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

4.  A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Masaki Terabe; Rima Koka; Debra D Donaldson; Elaine K Thomas; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

5.  Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Authors:  Ben C Creelan; Scott Antonia; David Noyes; Terri B Hunter; George R Simon; Gerold Bepler; Charles C Williams; Tawee Tanvetyanon; Eric B Haura; Michael J Schell; Alberto Chiappori
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

6.  Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.

Authors:  Z Dembic; K Schenck; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

7.  Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells.

Authors:  J Zhang; J K Zhang; S H Zhuo; H B Chen
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 8.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

9.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

10.  Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes.

Authors:  Zaher Hanna; Elena Priceputu; Pavel Chrobak; Chunyan Hu; Véronique Dugas; Mathieu Goupil; Miriam Marquis; Louis de Repentigny; Paul Jolicoeur
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.